In subgroup analyses (eTable 2 in Supplement 1), molnupiravir and nirmatrelvir-ritonavir users showed consistently lower risk of composite all-cause mortality and/or hospitalization compared with matched control participants, regardless of age, sex, baseline insulin use, and COVID-19 vaccination status. Here, INS is linked to COVID-19.